Heather Raymon
Senior Vice President - Research & Early Development Artiva Bio
Heather Raymon, Ph.D., has 25 years of biotech and biopharma industry experience. Prior to Artiva, Dr. Raymon was Executive Director, Early Development Program Leadership at Celgene/Bristol Myers Squibb, where she was leading multiple clinical-stage programs in immuno-oncology and neuroscience. Prior to that, Dr. Raymon was Sr. Director and Head of Pharmacology at Celgene, where she built a department that was responsible for developing pharmacology data packages in support of regulatory filings in oncology and inflammation/immunology. Dr. Raymon started her biotech career at Signal Pharmaceuticals working in neurobiology and cellular and molecular pharmacology before the company was acquired by Celgene. Dr. Raymon received her B.S. in biology from SUNY Albany, a Ph.D. in pharmacology and toxicology at UC Irvine, and was a postdoctoral fellow at Salk Institute for Biological Studies and UC San Diego.
Seminars
- Understanding the data needed to establish evidence-based guidelines for revaccination timing and efficacy following deep B-cell depletion
- Establishing a framework for determining the appropriate risk threshold for autoimmune patients to undergo deep B-cell depletion
- Defining long-term surveillance markers to monitor the safety of B-cell depletion therapies using longitudinal immune monitoring data
